NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership

Background: The NCI MATCH is an efficacy signal-finding trial to identify molecular alterations that can be matched to targeted treatments in tumor biopsies from patients (pts) with refractory solid tumors or lymphomas. NCI-MATCH opened in 8/2015, and a protocol-specified pause in screening for inte...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2016-12, Vol.69, p.S137-S137
Main Authors: Chen, A, Conley, B, Hamilton, S, Williams, M, O'Dwyer, P, Arteaga, C, Gray, R, McShane, L, Li, S, Rubinstein, L, Patton, D, Sazali, K, Zwiebel, J, Mitchell, E, Smith, M.L, Dragaud, D, Little, R, Comis, R, Abrams, J, Flaherty, K
Format: Article
Language:English
Subjects:
Biopsy
Breast cancer
Cancer therapies
Clinical trials
Colorectal cancer
Communities
Endometrium
Esophagus
Head
Hematology, Oncology and Palliative Medicine
Lung cancer
Lymphoma
Medical research
MLH1 protein
Molecular chains
MSH2 protein
Mutation
Neck
Pancreas
Prostate
Prostate cancer
PTEN protein
Solid tumors
Therapy
Toxicity
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The NCI MATCH is an efficacy signal-finding trial to identify molecular alterations that can be matched to targeted treatments in tumor biopsies from patients (pts) with refractory solid tumors or lymphomas. NCI-MATCH opened in 8/2015, and a protocol-specified pause in screening for interim analysis occurred in 11/2015. The trial reopened on 5/31/16 with revisions based on this analysis. Fourteen new targeted treatments were added (total 24 arms). Other changes include accepting biopsies 1 line of treatment or for which no standard of treatment is known, ECOG PS-1, acceptable organ function. Pts are either biopsied or have tissue available for analysis
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(16)33006-4